FI61194C - Foerfarande foer framstaellning av terapeutiskt anvaendbara adenosinnitrater - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara adenosinnitrater Download PDFInfo
- Publication number
- FI61194C FI61194C FI760184A FI760184A FI61194C FI 61194 C FI61194 C FI 61194C FI 760184 A FI760184 A FI 760184A FI 760184 A FI760184 A FI 760184A FI 61194 C FI61194 C FI 61194C
- Authority
- FI
- Finland
- Prior art keywords
- carboxylic acid
- nitroadenosine
- adenosine
- alkylamino
- formula
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims description 3
- 239000000853 adhesive Substances 0.000 title 1
- 230000001070 adhesive effect Effects 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 23
- -1 adenosine nitrates Chemical class 0.000 claims description 17
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 13
- 229960005305 adenosine Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009469 supplementation Effects 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000005490 tosylate group Chemical group 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FLLIEIALKHRKEE-VYJNXMPQSA-N [(2r,3r,4r,5r)-2-(2-amino-1-hydroxy-2-oxoethyl)-5-(6-aminopurin-9-yl)-4-nitrooxyoxolan-3-yl] nitrate Chemical compound [O-][N+](=O)O[C@@H]1[C@H](O[N+]([O-])=O)[C@@H](C(O)C(=O)N)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FLLIEIALKHRKEE-VYJNXMPQSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- ZYVNJOZSCBAXQU-CTQXGFPJSA-N ethyl 2-[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dinitrooxyoxolan-2-yl]-2-hydroxyacetate Chemical compound [O-][N+](=O)O[C@@H]1[C@H](O[N+]([O-])=O)[C@@H](C(O)C(=O)OCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZYVNJOZSCBAXQU-CTQXGFPJSA-N 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- BPJRMQVEUGXGQS-UVOYDWOXSA-N 2-[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dinitrooxyoxolan-2-yl]-2-hydroxyacetic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](C(O)C(O)=O)[C@@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O BPJRMQVEUGXGQS-UVOYDWOXSA-N 0.000 description 2
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 2
- IBYWUFHJUDTSOC-SOVPELCUSA-N 9-riburonosyladenine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H]1O IBYWUFHJUDTSOC-SOVPELCUSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- ZZFYTGDIVVDBLW-LFOXBMTCSA-N [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-[2-(dimethylamino)-1-hydroxy-2-oxoethyl]-4-nitrooxyoxolan-3-yl] nitrate Chemical compound [O-][N+](=O)O[C@@H]1[C@H](O[N+]([O-])=O)[C@@H](C(O)C(=O)N(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZZFYTGDIVVDBLW-LFOXBMTCSA-N 0.000 description 2
- ZBILUUMFUQQHTA-VDOIXTORSA-N [(2r,3s,4r,5r)-2-(2-amino-1-hydroxy-2-oxoethyl)-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-3-yl] nitrate Chemical compound O[C@@H]1[C@H](O[N+]([O-])=O)[C@@H](C(O)C(=O)N)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZBILUUMFUQQHTA-VDOIXTORSA-N 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 2
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VVIGFSVMHCPTEL-KQYNXXCUSA-N (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-nitrooxolane-3,4-diol Chemical class C1=NC=2C(N)=NC=NC=2N1[C@]1([N+]([O-])=O)O[C@H](CO)[C@@H](O)[C@H]1O VVIGFSVMHCPTEL-KQYNXXCUSA-N 0.000 description 1
- BLMHAOGGJQDPLX-LKCKTBJASA-N (2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)N)O[C@H]1N1C2=NC=NC(N)=C2N=C1 BLMHAOGGJQDPLX-LKCKTBJASA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- YKMOOBLAWBCXFX-UHFFFAOYSA-N 2-(2,4-dinitrophenyl)ethanamine Chemical compound NCCC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O YKMOOBLAWBCXFX-UHFFFAOYSA-N 0.000 description 1
- RGCNCGQMLPHBCH-LFOXBMTCSA-N 2-[[2-[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dinitrooxyoxolan-2-yl]-2-hydroxyacetyl]amino]ethyl nitrate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](C(O)C(=O)NCCO[N+]([O-])=O)[C@@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O RGCNCGQMLPHBCH-LFOXBMTCSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
- JLNTWVDSQRNWFU-UHFFFAOYSA-N OOOOOOO Chemical compound OOOOOOO JLNTWVDSQRNWFU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- HGAINSFYKFBBNN-GMAQNGDPSA-N [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-(1-hydroxy-2-oxo-2-piperidin-1-ylethyl)-4-nitrooxyoxolan-3-yl] nitrate Chemical compound OC([C@H]1O[C@H]([C@@H]([C@@H]1O[N+]([O-])=O)O[N+]([O-])=O)N1C=2N=CN=C(C=2N=C1)N)C(=O)N1CCCCC1 HGAINSFYKFBBNN-GMAQNGDPSA-N 0.000 description 1
- MHRBDNKQWGCSID-AFJSHLQXSA-N [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-[1-hydroxy-2-oxo-2-(propan-2-ylamino)ethyl]-4-nitrooxyoxolan-3-yl] nitrate Chemical compound [O-][N+](=O)O[C@@H]1[C@H](O[N+]([O-])=O)[C@@H](C(O)C(=O)NC(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MHRBDNKQWGCSID-AFJSHLQXSA-N 0.000 description 1
- NAGZDRLNJYSQAF-LDMIVLQTSA-N [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-[2-(cyclohexylamino)-1-hydroxy-2-oxoethyl]-4-nitrooxyoxolan-3-yl] nitrate Chemical compound OC([C@H]1O[C@H]([C@@H]([C@@H]1O[N+]([O-])=O)O[N+]([O-])=O)N1C=2N=CN=C(C=2N=C1)N)C(=O)NC1CCCCC1 NAGZDRLNJYSQAF-LDMIVLQTSA-N 0.000 description 1
- NDCVVFAXHSQDQC-BDRODDNVSA-N [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-2-[2-(dimethylamino)-1-hydroxy-2-oxoethyl]-4-hydroxyoxolan-3-yl] nitrate Chemical compound O[C@@H]1[C@H](O[N+]([O-])=O)[C@@H](C(O)C(=O)N(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NDCVVFAXHSQDQC-BDRODDNVSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000003835 adenosine derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BKAVNBXDMBQWOK-FEPCECHZSA-N ethyl 2-[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-nitrooxyoxolan-2-yl]-2-hydroxyacetate Chemical compound O[C@@H]1[C@H](O[N+]([O-])=O)[C@@H](C(O)C(=O)OCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 BKAVNBXDMBQWOK-FEPCECHZSA-N 0.000 description 1
- APOMUSUCVBJIJE-ICYLAYCASA-N ethyl 2-[(2s,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-4-nitrooxolan-2-yl]-2-hydroxyacetate Chemical compound [O-][N+](=O)[C@@]1(O)[C@H](O)[C@@H](C(O)C(=O)OCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 APOMUSUCVBJIJE-ICYLAYCASA-N 0.000 description 1
- BPASLSSCGMNTIG-ZXCJZDNZSA-N ethyl 2-[(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetate Chemical compound O[C@@H]1[C@H](O)[C@@H](C(O)C(=O)OCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 BPASLSSCGMNTIG-ZXCJZDNZSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- MQOSZVYMJCFFCW-HDKLIBPASA-N propan-2-yl 2-[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dinitrooxyoxolan-2-yl]-2-hydroxyacetate Chemical compound [O-][N+](=O)O[C@@H]1[C@H](O[N+]([O-])=O)[C@@H](C(O)C(=O)OC(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MQOSZVYMJCFFCW-HDKLIBPASA-N 0.000 description 1
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH203275A CH606084A5 (en) | 1975-02-18 | 1975-02-18 | (Di) nitrates of adenosine -5'-carboxylic acid derivs |
| CH203275 | 1975-02-18 | ||
| CH874875 | 1975-07-04 | ||
| CH874875 | 1975-07-04 | ||
| CH1609475 | 1975-12-11 | ||
| CH1609475A CH612948A5 (en) | 1975-12-11 | 1975-12-11 | Process for the preparation of adenosine nitrates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI760184A7 FI760184A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-08-19 |
| FI61194B FI61194B (fi) | 1982-02-26 |
| FI61194C true FI61194C (fi) | 1982-06-10 |
Family
ID=27173417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI760184A FI61194C (fi) | 1975-02-18 | 1976-01-27 | Foerfarande foer framstaellning av terapeutiskt anvaendbara adenosinnitrater |
Country Status (23)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310731A (en) * | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
| EP2876166B1 (en) | 2013-11-20 | 2016-12-14 | Roche Diagnostics GmbH | New compound for sequencing by synthesis |
-
1976
- 1976-01-16 IL IL48854A patent/IL48854A/xx unknown
- 1976-01-20 NZ NZ179785A patent/NZ179785A/xx unknown
- 1976-01-20 AU AU10428/76A patent/AU497075B2/en not_active Expired
- 1976-01-22 NL NL7600663A patent/NL7600663A/xx not_active Application Discontinuation
- 1976-01-27 FI FI760184A patent/FI61194C/fi not_active IP Right Cessation
- 1976-02-04 CA CA245,008A patent/CA1050534A/en not_active Expired
- 1976-02-11 IE IE267/76A patent/IE43210B1/en unknown
- 1976-02-11 HU HU76HO00001875A patent/HU172959B/hu unknown
- 1976-02-13 PH PH18105A patent/PH15859A/en unknown
- 1976-02-16 FR FR7604163A patent/FR2301264A1/fr active Granted
- 1976-02-16 LU LU74356A patent/LU74356A1/xx unknown
- 1976-02-16 JP JP51014997A patent/JPS51105095A/ja active Pending
- 1976-02-16 SE SE7601725A patent/SE423237B/xx unknown
- 1976-02-16 GR GR50064A patent/GR59304B/el unknown
- 1976-02-17 GB GB6162/76A patent/GB1489327A/en not_active Expired
- 1976-02-17 PT PT64811A patent/PT64811B/pt unknown
- 1976-02-17 BR BR7600997A patent/BR7600997A/pt unknown
- 1976-02-17 DD DD191276A patent/DD124252A5/xx unknown
- 1976-02-17 ES ES445234A patent/ES445234A1/es not_active Expired
- 1976-02-17 NO NO760520A patent/NO141652C/no unknown
- 1976-02-17 DK DK62776AA patent/DK136957B/da not_active IP Right Cessation
- 1976-02-18 DE DE19762606532 patent/DE2606532A1/de not_active Withdrawn
- 1976-03-05 AR AR262163A patent/AR217398A1/es active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI60555C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara aromatiska karboxylamidderivat | |
| PL117996B1 (en) | Process for preparing novel,optically active phenethanoloamineslaminov | |
| EP0253257A2 (de) | Substituierte Amino -5,6,7,8-tetrahydronaphtyl-oxyessigsäuren, Verfahren zu deren Herstellung sowie die Verwendung als Arzneimittel | |
| DE2106209B2 (de) | p-substituierte Phenoxypropanolamine, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis | |
| EP0705244A1 (de) | Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems | |
| CN101906039A (zh) | 取代苯酚的羟基酸酯化合物、制备方法及在药物中的应用 | |
| JPH0559096A (ja) | 新規アミノステロイド化合物 | |
| CN101362702A (zh) | 大黄素衍生物及其在制备抗癌药物中的应用 | |
| US5094782A (en) | Synthesis of capsacin derivatives and their use as an analgesic drug and vessel dilation drug | |
| DE2925945A1 (de) | Acylderivate von carnitin, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel | |
| CH629178A5 (it) | Procedimento per la preparazione di nuovi esteri della epinina. | |
| DE69023980T2 (de) | 2-(RS)-substituierte-2,3-dihydro-5-oxy-4,6,7-trimethyl-benzofurane, verwendbar als antioxydante Arzneimittel mit mukoregulierender und anti-ischemischer Wirkung. | |
| RU1830063C (ru) | Способ получени замещенных 1-(1Н-имидазол-4-ил)-алкилбензамидов или их солей присоединени с кислотами нетоксичными и фармацевтически приемлемыми | |
| CA2873093A1 (en) | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders | |
| Chen et al. | Hypotensive and antinociceptive effects of ether-linked and relatively non-pungent analogues of N-nonanoyl vanillylamide | |
| FI61194C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara adenosinnitrater | |
| DK147795B (da) | Analogifremgangsmaade til fremstilling af xanthinderivater | |
| PT98121B (pt) | Processo para a preparacao de novos 3,3'-ditio-bis (acidos propionicos) e seus esteres e de composicoes farmaceuticas que os contem | |
| JP5849336B2 (ja) | アデニル酸シクラーゼの活性調節剤 | |
| EP3059232A1 (en) | Chromene derivatives substituted by alkoxide as inhibitors of the tcr-nck interaction | |
| PT85608B (pt) | Processo para a preparacao de derivados de fenil-etanolamina | |
| DE2329745C2 (de) | Arzneimittel gegen Viren der Picorna-Gruppe | |
| EP1946758A1 (en) | Treatment of acute myeloid leukemia | |
| DE3853958T2 (de) | Substituierte Pyridin-Verbindungen, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen. | |
| US3876683A (en) | (n-carboxymethyl)biphenyl acetamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: F. HOFFMANN-LA ROCHE & CO. |